Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step following criticism from President Trump.
Stories Related to Novartis Won't Raise U.s. Drug Prices This Year
WSJ.com: Asia Home, Wall Street Journal: Home Asia
Wed, 07/18/2018 - 1:46pm
RELATED ARTICLES
- Stocks Fall as Investors Pause on Trade
Stocks fell, erasing early gains as investors continued to track trade negotiations between the U.S. and China as the two nations appear to inch closer to a pact. More - House Panel Requests Documents From Associates of Trump
Democrats intensified their investigations into President Trump and his associates, with House committees demanding records related to his business dealings, interactions with the Justice Department and communications with Russian President Vladimir Putin. More - U.S. Probes Titanium Imports in Possible Tariff Case
The Commerce Department will look into potential national-security risks in imports of the metal at the request of domestic producer Timet. More - China Accuses Detained Canadians of Espionage
China accused two detained Canadians of working together to steal Chinese state secrets, moving ahead with a politically charged investigation seen as retribution for Canada’s arrest of a senior Huawei executive. More - North Korea Still Using Uranium-Enrichment Facility, U.N. Agency Says
North Korea is still using a uranium-enrichment facility at the heart of last week’s summit between President Trump and North Korean leader Kim Jong Un, the United Nations atomic agency said. More - Purdue Pharma Preparing Possible Bankruptcy Filing
Purdue Pharma is working with advisers on a possible bankruptcy filing as it seeks to contain liability from suits alleging it fueled the U.S. opioid epidemic. More
BING NEWS:
- 25K Americans starting Wegovy weekly as supply increases and prices drop, drugmaker says
The number of U.S. patients currently starting the weight management drug Wegovy is "four times" the number in December 2023, the drugmaker said.
05/4/2024 - 2:41 am | View Link - ICER casts doubt on Sarepta’s DMD gene therapy
The drug-pricing watchdogs over at the Institute for Clinical and Economic Review tend to be supportive of gene therapy pricing, even when the price is steep. That makes the doubt its casting on ...
05/3/2024 - 2:15 am | View Link - Novo Nordisk: Wegovy, Ozempic prices fell in the first quarter
Wegovy prices in the United States were "slightly down" in the first quarter and Novo expects further decreases through the rest of 2024, ...
05/2/2024 - 4:12 am | View Link - Weight-loss drug Wegovy available in Canada starting May 6
The makers of Ozempic say their weight-loss drug Wegovy will be available to patients in Canada starting Monday.
05/1/2024 - 11:30 pm | View Link - Healthcare and drugmaker groups seek to revive challenge to US drug-pricing law
Healthcare and drug industry groups on Wednesday urged a U.S. appeals court to revive their challenge to a law requiring manufacturers to negotiate the prices of some drugs with the U.S government's ...
05/1/2024 - 10:19 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more